These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16673686)

  • 1. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure.
    Riou França L; Launois R; Le Lay K; Aegerter P; Bouhassira M; Meshaka P; Guidet B
    Int J Technol Assess Health Care; 2006; 22(1):101-8. PubMed ID: 16673686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.
    Green C; Dinnes J; Takeda A; Shepherd J; Hartwell D; Cave C; Payne E; Cuthbertson BH
    Health Technol Assess; 2005 Mar; 9(11):1-126, iii-iv. PubMed ID: 15774234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany.
    Neilson AR; Burchardi H; Chinn C; Clouth J; Schneider H; Angus D
    J Crit Care; 2003 Dec; 18(4):217-27. PubMed ID: 14691895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.
    Betancourt M; McKinnon PS; Massanari RM; Kanji S; Bach D; Devlin JW
    Pharmacoeconomics; 2003; 21(18):1331-40. PubMed ID: 14750900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain].
    Sacristán JA; Prieto L; Huete T; Artigas A; Badia X; Chinn C; Hudson P
    Gac Sanit; 2004; 18(1):50-7. PubMed ID: 14980173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.
    Angus DC; Linde-Zwirble WT; Clermont G; Ball DE; Basson BR; Ely EW; Laterre PF; Vincent JL; Bernard G; van Hout B;
    Crit Care Med; 2003 Jan; 31(1):1-11. PubMed ID: 12544986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.
    Frampton JE; Foster RH
    Pharmacoeconomics; 2004; 22(7):445-76. PubMed ID: 15137883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
    Davies A; Ridley S; Hutton J; Chinn C; Barber B; Angus DC
    Anaesthesia; 2005 Feb; 60(2):155-62. PubMed ID: 15644013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
    Green C; Dinnes J; Takeda AL; Cuthbertson BH
    Int J Technol Assess Health Care; 2006; 22(1):90-100. PubMed ID: 16673685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drotrecogin alfa (activated) for severe sepsis.
    Drug Ther Bull; 2006 Jan; 44(1):5-8. PubMed ID: 16425899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
    Sadique MZ; Grieve R; Harrison DA; Cuthbertson BH; Rowan KM
    Crit Care; 2011; 15(5):R228. PubMed ID: 21943177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of drotrecogin alfa (activated) on resource use and implications for reimbursement.
    Dasta JF; Cooper LM
    Pharmacotherapy; 2002 Dec; 22(12 Pt 2):216S-222S. PubMed ID: 12492228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimate of the number of patients eligible for treatment with drotrecogin alfa (activated) based on differing international indications: post-hoc analysis of an inception cohort study in Australia and New Zealand.
    Finfer S; Felton T; Blundell A; Lipman J;
    Anaesth Intensive Care; 2006 Apr; 34(2):184-90. PubMed ID: 16617638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management challenge with drotrecogin alfa (activated).
    Vanscoy GJ
    Am J Health Syst Pharm; 2002 Feb; 59 Suppl 1():S23-9. PubMed ID: 11885411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local treatment pattern versus trial-based data: a cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden.
    Hjelmgren J; Persson U; Tennvall GR
    Am J Ther; 2005; 12(5):425-30. PubMed ID: 16148428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term cost effectiveness of drotrecogin alfa (activated): an unanswered question.
    Banks SM; Gerstenberger E; Eichacker PQ; Natanson C
    Crit Care Med; 2003 Jan; 31(1):308-9. PubMed ID: 12545035
    [No Abstract]   [Full Text] [Related]  

  • 17. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
    Bernard GR; Margolis BD; Shanies HM; Ely EW; Wheeler AP; Levy H; Wong K; Wright TJ;
    Chest; 2004 Jun; 125(6):2206-16. PubMed ID: 15189943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
    Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
    Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy.
    Sollet JP; Garber GE
    Am J Surg; 2002 Dec; 184(6A Suppl):S11-8. PubMed ID: 12521613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drotrecogin alfa (recombinant human activated protein C) in severe sepsis--a New Zealand viewpoint.
    Liang J; Streat S; Torrance J; Sleigh J; Freebairn R; Ramsay M
    N Z Med J; 2003 Sep; 116(1181):U586. PubMed ID: 14581969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.